At the bedside: adoptive cell therapy for melanoma-clinical development
about
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsChimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitroOncolytic virus immunotherapy for melanoma.Targeting Melanoma with Cancer-Killing Viruses.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.
P2860
At the bedside: adoptive cell therapy for melanoma-clinical development
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
At the bedside: adoptive cell therapy for melanoma-clinical development
@ast
At the bedside: adoptive cell therapy for melanoma-clinical development
@en
At the bedside: adoptive cell therapy for melanoma-clinical development
@nl
type
label
At the bedside: adoptive cell therapy for melanoma-clinical development
@ast
At the bedside: adoptive cell therapy for melanoma-clinical development
@en
At the bedside: adoptive cell therapy for melanoma-clinical development
@nl
prefLabel
At the bedside: adoptive cell therapy for melanoma-clinical development
@ast
At the bedside: adoptive cell therapy for melanoma-clinical development
@en
At the bedside: adoptive cell therapy for melanoma-clinical development
@nl
P356
P1476
At the bedside: adoptive cell therapy for melanoma-clinical development
@en
P2093
J. S. Weber
P304
P356
10.1189/JLB.0513293
P407
P577
2014-06-01T00:00:00Z